Century Therapeutics, Inc. (IPSC)
1.41
+0.04
(+2.92%)
USD |
NASDAQ |
Nov 18, 11:13
Century Therapeutics Enterprise Value : 168.59M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 168.59M |
| November 16, 2026 | 217.53M |
| November 13, 2026 | 219.34M |
| November 12, 2026 | 215.72M |
| November 11, 2026 | 235.65M |
| November 10, 2026 | 224.78M |
| November 09, 2026 | 248.34M |
| November 06, 2026 | 224.78M |
| November 05, 2026 | 193.97M |
| November 04, 2026 | 222.97M |
| November 03, 2026 | 195.78M |
| November 02, 2026 | 188.53M |
| October 30, 2026 | 186.72M |
| October 29, 2026 | 184.91M |
| October 28, 2026 | 192.16M |
| October 27, 2026 | 183.09M |
| October 26, 2026 | 177.66M |
| October 23, 2026 | 184.91M |
| October 22, 2026 | 206.66M |
| October 21, 2026 | 212.09M |
| October 20, 2026 | 217.53M |
| October 19, 2026 | 186.72M |
| October 16, 2026 | 168.59M |
| October 15, 2026 | 192.16M |
| October 14, 2026 | 170.41M |
| Date | Value |
|---|---|
| October 13, 2026 | 170.41M |
| October 12, 2026 | 181.28M |
| October 09, 2026 | 186.72M |
| October 08, 2026 | 184.91M |
| October 07, 2026 | 152.28M |
| October 06, 2026 | 159.53M |
| October 05, 2026 | 188.53M |
| October 02, 2026 | 197.59M |
| October 01, 2026 | 212.09M |
| September 30, 2026 | 230.22M |
| September 29, 2026 | 216.86M |
| September 28, 2026 | 220.47M |
| September 25, 2026 | 220.47M |
| September 24, 2026 | 224.08M |
| September 23, 2026 | 236.72M |
| September 22, 2026 | 260.19M |
| September 21, 2026 | 252.97M |
| September 18, 2026 | 254.77M |
| September 17, 2026 | 258.38M |
| September 16, 2026 | 254.77M |
| September 15, 2026 | 276.44M |
| September 14, 2026 | 280.05M |
| September 11, 2026 | 269.22M |
| September 10, 2026 | 269.22M |
| September 09, 2026 | 285.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -49.07M |
| Exicure, Inc. | 5.167M |
| Absci Corp. | 1.136B |
| Celularity, Inc. | 85.97M |
| Cardio Diagnostics Holdings, Inc. | 1.357M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.45M |
| Total Expenses (Quarterly) | 23.45M |
| EPS Diluted (Quarterly) | -0.1136 |
| Earnings Yield | -43.43% |
| Normalized Earnings Yield | -44.47 |